In this issue of JAMA, Borlaug and colleagues report the results of a important clinical trial, which are likely to alter paradigms and clinical guidelines for heart failure with preserved ejection fraction (HFpEF). The prevalence of this syndrome has progressively increased, and HFpEF has become the most common form of heart failure, particularly in older persons, women, and Black individuals. It affects more than 3 million people in the US and is associated with severe symptoms of exertional dyspnea and fatigue (exercise intolerance), impaired health-related quality of life, severely reduced exercise capacity (the primary outcome in the current trial), and increased rates of rehospitalizations and death.
Source: JAMA Online First